下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age.
我们的研究表明,年轻的BC患者TIL密度显著高于年长患者。这些差异可能影响高免疫原性亚型的治疗效果。
围绕癌症的淋巴细胞参与肿瘤相关免疫反应,被称为TIL(肿瘤浸润淋巴细胞)(TILs)。近期多项报道提示,TILs可反映肿瘤微环境并预测化疗的治疗效果。然而,仅有少数研究探讨了年龄与TILs之间的关系。衰老会降低宿主免疫力,我们预测它也可能影响TILs。因此,我们假设老年乳腺癌(BC)患者的TIL密度可能低于年轻BC患者。在此,我们回顾性分析了年龄小于45岁与大于60岁的BC患者之间TILs的差异以及术前化疗(POC)的治疗效果。
我们回顾性分析了356例接受POC的乳腺癌患者数据,其中包括75例年龄≤45岁的患者和116例年龄>60岁的患者。使用治疗前穿刺活检标本,通过Student's t检验比较各年龄组的TIL密度。在分析影响TIL密度的不同因素后,还检查了预后因素。
年龄较大的三阴性BC患者TIL密度显著低于年轻患者,而在人表皮生长因子受体2(HER2)富集型BC中,年轻年龄组的TIL密度显著高于年龄较大组。此外,年轻HER2富集型乳腺癌患者的完全病理缓解率显著高于年龄较大的HER2富集型BC患者。此外,在这些三阴性BC患者中观察到总生存期存在显著差异。
BACKGROUND: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have studied the relationship between age and TILs. Aging reduces host immunity, and we predict that it may also affect TILs. Thus, we hypothesized that older breast cancer (BC) patients may have low TIL density than younger BC patients. Here, we retrospectively analyzed the differences in TILs by age and the therapeutic effects of preoperative chemotherapy (POC) in BC patients who were aged either less than 45 years or more than 60 years. METHODS: We retrospectively examined the data of 356 breast cancer patients who underwent POC, including 75 patients aged 45 years and 116 patients aged > 60 years. Using pre-treatment needle biopsy specimens, TIL density was compared for each age group by Student's t-test. After analyzing different factors that affect TIL density, prognostic factors were also examined. RESULTS: Older patients with triple-negative BC had significantly lower TIL density than younger patients, while in human epidermal growth factor receptor 2 (HER2)-enriched BC, TIL density was significantly higher in the younger age group than that in the older age group. In addition, younger patients with HER2-rich breast cancer showed significantly higher complete pathological response rates than older patients with HER2-rich BC. In addition, significant differences in overall survival were observed among these patients with triple-negative BC. CONCLUSIONS: Our study suggests that younger BC patients possess significantly higher TIL density than older patients. These differences may influence the therapeutic efficacy in highly immunogenic subtypes.
MEMBER ACCOUNT
登录成功会直接打开下一页。